Aurobindo Pharma Reports 32% Rise in Q2 Net Profit to ₹1,124 Crore

Hyderabad-based pharmaceutical company Aurobindo Pharma has reported a consolidated net profit of ₹1,124 crore for the second quarter of the current financial year ended September 30, 2026. This represents a 32.5 percent increase compared to the ₹848 crore net profit recorded in the corresponding quarter of the previous financial year.

Alongside the growth in net profit, the company registered total revenue of ₹10,263 crore for the quarter. This marks a 24 percent increase from the ₹8,286 crore reported in the year-ago period. According to the company, this figure represents its highest-ever quarterly revenue, driven by broad-based growth across its business segments.

Commenting on the performance, K Nithyananda Reddy, Vice-Chairman and Managing Director of Aurobindo Pharma, stated that the results reflect the strength of the company's business fundamentals, execution capabilities, and the resilience of its diversified product portfolio. He noted that the growth was supported by organic momentum across key businesses and the integration of inorganic opportunities.

Reddy further stated that the company remains focused on sustainable growth, financial discipline, and value creation for stakeholders while expanding access to affordable healthcare globally as it advances its strategic priorities.

"Aurobindo Pharma's latest quarterly performance demonstrates the importance of balancing organic growth with strategic inorganic integration. Achieving their highest-ever quarterly revenue of over ₹10,000 crore highlights operational resilience and a strong diversified product portfolio. For businesses and enterprises scaling up, maintaining financial discipline while expanding market reach remains a critical blueprint for sustainable long-term value creation." — Dr. Shishir Gupta, Founder & CEO, StartupLanes